Is It Possible to Intervene in the Capacity of *Trypanosoma cruzi* to Elicit and Evade the Complement System?

Galia Ramírez-Toloza1*, Lorena Aguilar-Guzmán2, Carolina Valck3, Smrithi S. Menon4, Viviana P. Ferreira4* and Arturo Ferreira3*

1 Department of Preventive Veterinary Medicine, Faculty of Veterinary Medicine and Livestock Sciences, University of Chile, Santiago, Chile, 2 Department of Pathology, Faculty of Veterinary Medicine and Livestock Sciences, University of Chile, Santiago, Chile, 3 Department of Immunology, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Santiago, Chile, 4 Department of Medical Microbiology and Immunology, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, United States

Chagas’ disease is a zoonotic parasitic ailment now affecting more than 6 million people, mainly in Latin America. Its agent, the protozoan *Trypanosoma cruzi*, is primarily transmitted by endemic hematophagous triatomine insects. Transplacental transmission is also important and a main source for the emerging global expansion of this disease. In the host, the parasite undergoes intra (amastigotes) and extracellular infective (trypomastigotes) stages, both eliciting complex immune responses that, in about 70% of the cases, culminate in permanent immunity, concomitant with the asymptomatic presence of the parasite. The remaining 30% of those infected individuals will develop a syndrome, with variable pathological effects on the circulatory, nervous, and digestive systems. Herein, we review an important number of *T. cruzi* molecules, mainly located on its surface, that have been characterized as immunogenic and protective in various experimental setups. We also discuss a variety of parasite strategies to evade the complement system - mediated immune responses. Within this context, we also discuss the capacity of the *T. cruzi* infective trypomastigote to translocate the ER-resident chaperone calreticulin to its surface as a key evasive strategy. Herein, it is described that *T. cruzi* calreticulin inhibits the initial stages of activation of the host complement system, with obvious benefits for the parasite. Finally, we speculate on the possibility to experimentally intervene in the interaction of calreticulin and other *T. cruzi* molecules that interact with the complement system; thus resulting in significant inhibition of *T. cruzi* infectivity.

Keywords: *Trypanosoma cruzi*, host-parasite interaction, complement system, complement regulatory proteins, host-immune evasion
INTRODUCTION

Chagas disease, or American trypanosomiasis, is a multisystemic disorder that affects the cardiovascular, digestive, and central nervous systems (1). Chagas disease is one of the 20 most “neglected tropical diseases”, as defined by The World Health Organization (WHO) (2). About 6-7 million people are infected worldwide, with almost 100 million at risk, indicating that this disease is a serious public health issue (3, 4). In endemic countries, Chagas disease is primarily transmitted by triatomine vectors, predominantly in rural areas. However, human migration and other forms of transmission have changed the epidemiology/epizootiology of Chagas disease, which is currently affecting peri-urban and urban areas (5, 6). Other important mechanisms of transmission include blood transfusion, organ transplants, oral ingestion, laboratory accidents, vertical transmission from mother to child, or needle sharing (2, 7).

Chagas disease is caused by Trypanosoma cruzi (T. cruzi), a hemoflagellate parasite transmitted through various species of hematophagous reduviid insects (‘kissing bugs’) mainly in endemic areas such as Latin America (8). Trypomastigotes, the infective form, circulate in the blood of mammals and infect nucleated cells, where they transform into amastigotes, the infective form, circulate in the blood of mammals and infect nucleated cells, where they transform into amastigotes, the replicative form. T. cruzi needs to evade the host immune system, especially during the acute phase of the infection, and various mechanisms have been described for the parasite to control the innate and adaptive host immune responses. In the regulation of adaptive immune responses, inhibition of polyclonal activation of B and T cells may be relevant in infected people (9) and in mice (10, 11). Additionally, a decrease in the proliferative response of lymphocytes, as well as in the production of interleukin-2 (IL-2) in chronic Chagas disease patients has also been reported (12). Moreover, the parasites induce immunomodulatory molecules, such as IL-10 and transforming growth factor-β (TGF-β), which lead to failure in the maturation of antigen-presenting cells and poor antigenic presentation (12).

To evade the innate immune response, one of the most important mechanisms adopted by T. cruzi is to modulate complement system (C) activity (Figure 1). Thus, infective trypomastigotes, are resistant to C, while non-infective epimastigotes, present in the reduviid insect vector, are extremely sensitive (13, 14). However, this C resistance varies among T. cruzi strains (15), being mediated by (a) surface expression of molecules such as glycoprotein 58/68 (gp 58/68) (16), T. cruzi complement regulatory protein (TcCRP) (17–19), T. cruzi trypomastigote-decay accelerating factor (T-DAF) (20, 21), T. cruzi calreticulin (TcCalr) (22), C2 receptor inhibitor trispanning (CRIT) (Table 1) and/or (b) secretion or acquisition of molecules from host blood stream, such as Factor H (FH) (36), and T. cruzi induced host extracellular vesicles (EV) (37). These molecules inhibit C at the initial steps of the cascade or inhibit C3 and/or C5 convertases of the classical (CP), lectin (LP) and/or alternative (AP) pathways (37) (Figure 1). However, studies on their therapeutic or prophylactic values are still limited. Herein, we will focus on the interactions of these molecules with C, and in their potential therapeutic/prophylactic roles.

T. CRUZI MOLECULES INHIBITING C AT THE INITIAL STEPS

T. cruzi complement C2 receptor inhibitor trispanning protein (CRIT), a 32 kDa protein containing a 27 amino acid extracellular domain (38–40), is a C2 receptor, present on T. cruzi, that inhibits C2 cleavage by C1s (38). First described in the Y strain, CRIT expressed on trypomastigotes binds to, and inactivates C2, inhibiting the CP and LP (23). The same group then showed that in the LP, the extracellular domain 1 of CRIT inhibits MBL-Associated Serine Protease-2 (MASP-2) mediated C2 cleavage, thus impairing formation of the C3 convertase (24). Thus, parasites overexpressing CRIT are highly resistant to C-mediated lysis (24). CRIT is expressed in different T. cruzi strains and clones, such as CL Brenner, Colombiana and Dm28c, with high sequence identity (88 - 98%) (23), but apparently its gene is only functional in some T. cruzi lineages. A recent study evaluating the resistance of C in different Tc1 strains with high (Qro) and low (Ninoa) virulence, demonstrated that the mRNA of CRIT is three – fold lower in the low virulence strain (41).

T. cruzi calreticulin (TcCalr) (formerly known as TcCRT), is a highly pleiotropic protein, with inhibitory effects in C activation and infectivity. In addition to these roles, TcCalr, also reduces angiogenesis and tumor growth, however, these roles have been described and reviewed elsewhere (25, 42–46). Infective trypomastigotes carrying a monoallelic deletion of the TcCalr gene, are significantly susceptible to C-mediated lysis. On the contrary, parasites overexpressing TcCalr are significantly more resistant to CP and LP-mediated lysis (26, 47). TcCalr binds to the collagenous tails of C1q, inhibiting the CP (22). Its central TcCalr S-domain (aa 159-281) competes with the (C1r-C1s)2 tetrameric complex to bind C1q, thus decreasing C4b generation and in turn decreasing the levels of the generated CP C3 and C5 convertases (22). Furthermore, both CP serine-proteases, C1s and C1r, bind TcCalr in vitro, but TcCalr does not inhibit the C4-activating function of solid phase-bound C1s. Perhaps, C1s inactivation occurs only when the serine protease is part of C1 complex (C1q, (C1r, C1s)2) (27). Additionally, TcCalr competes with the capacity of the serine proteases to bind C1q, but does not displace them from the preformed C1 complex (27). In Chagas disease, this role may be also important in other steps of the parasite cycle, since Triatoma infestans calreticulin (TiCalr), present in the insect’s saliva, also binds C1, inhibiting the CP. Perhaps, TiCalr prevents mammal C-mediated damage to the vector’s digestive mucosa (48). TcCalr and its S-domain (aa 159-281) also binds mannan-binding lectin (MBL) and Ficolins, inhibiting the LP (22, 28). Although TcCalr binds to the collagenous tails of MBL and reduces the binding of MBL to mannose, it does not inhibit C4 activation (22). On the other hand, L-Ficolin (but not H-Ficolin) binds to TcCalr, interfering with its activation via Lipoteichoic-acid. Moreover, because trypomastigotes translocate significantly higher amounts of TcCalr to their surfaces, L-Ficolin binds preferentially to this infectious stage of the parasite (28). Thus, TcCalr inhibits both CP and LP (22, 27, 28).

TcCalr is an ER-resident protein that translocates to the parasite external microenvironment. Although TcCalr is located
mainly in the ER, it is also found in the Golgi, reservosomes, flagellar pocket, cell surface, cytosol, nucleus and kinetoplast (22, 49, 50). Thus, C1q and TcCalr colocalize on the parasite surface, mainly on the area of flagellar emergence (16). It is well known that CALR (the human TcCalr counterpart), participates as an “eat me” signal in apoptotic cancer cells, promoting their phagocytosis (51). This process is mediated by the CALR/C1q interaction on the apoptotic cells, which also generates C5 convertases that produce the split products C5a and C5b. (3) In the late step, C5b anchored to the pathogen surfaces, in conjunction with C6-C9, form the membrane attack complex (MAC) and lyse the pathogen. Thus, C activation induces opsonization (by C3b and C4b), inflammation (by C3a and C5a) and lysis of microorganisms such as T. cruzi. However, C activation is stringently controlled by C regulatory proteins. The membrane bound regulatory proteins are: Decay-accelerating factor (DAF), membrane co-factor protein (MCP), C receptor 1 (CR-1) CDS9 and complement receptor of immunoglobulin family (CRlg) (in green). Regulatory proteins found in plasma are: Factor I, Factor H, C4 binding protein (C4BP), C1-inhibitor (C1-Inh), S-protein and Clusterin (in blue). These proteins limit amplification of the downstream cascade. To evade C activation, Trypanosoma cruzi expresses and secretes complement regulatory proteins with homologous function with their human counterparts (in red). Thus, CRIT and TcCalr inhibit C in early stages of activation, and T-DAF, TcCRP and gp58/68 participate in intermediate stages of activation.

FIGURE 1 | Trypanosoma cruzi expresses, secretes, or recruits complement regulatory proteins and intervening in the interaction of these T. cruzi-derived regulatory proteins with complement can affect host-parasite interactions. The complement system (C) is activated by three different pathways: classical (CP), lectin (LP) and alternative (AP). (1) In the initiation steps, these pathways are activated by the identification of different pathogen-associated molecular patterns (PAMPs) present on microorganisms such as T. cruzi. Thus, the CP is activated when C1 complex (C1q,f,Ig) recognizes antibodies bound to T. cruzi or acute phase proteins. The LP is activated when MBL and ficolins form complexes with serine proteases (MASPs) in the presence of carbohydrates. The AP is activated by spontaneous hydrolysis of C3, near a variety of non-self cell surfaces. (2) In the early steps, all activated pathways converge in the generation of C3 convertases, that continuously cleave C3 into C3a and C3b continuing with the enzymatic cascade that also generates C5 convertases that produce the split products C5a and C5b. (3) Finally, in the late step, C5b anchored to the pathogen surfaces, in conjunction with C6-C9, form the membrane attack complex (MAC) and lyse the pathogen. Thus, C activation induces opsonization (by C3b and C4b), inflammation (by C3a and C5a) and lysis of microorganisms such as T. cruzi. However, C activation is stringently controlled by C regulatory proteins. The membrane bound regulatory proteins are: Decay-accelerating factor (DAF), membrane co-factor protein (MCP), C receptor 1 (CR-1) CDS9 and complement receptor of immunoglobulin family (CRlg) (in green). Regulatory proteins found in plasma are: Factor I, Factor H, C4 binding protein (C4BP), C1-inhibitor (C1-Inh), S-protein and Clusterin (in blue). These proteins limit amplification of the downstream cascade. To evade C activation, Trypanosoma cruzi expresses and secretes complement regulatory proteins with homologous function with their human counterparts (in red). Thus, CRIT and TcCalr inhibit C in early stages of activation, and T-DAF, TcCRP and gp58/68 participate in intermediate stages of activation.
TABLE 1 | Complement regulatory proteins expressed and/or secreted by Trypanosoma cruzi, their roles in the host-parasite interaction and as potential therapeutic or prophylactic tools.

| Complement regulatory protein | Functions in Complement system evasion | Other roles in the host-parasite interaction | Therapeutic or prophylactic potential | Reference |
|-------------------------------|---------------------------------------|--------------------------------------------|--------------------------------------|----------|
| Trypanosoma cruzi Receptor Inhibitor Tripanning Protein (CRIT) | CRIT is a 32 kDa protein that inhibits the C2 cleavage by C1s and MASP2 and impairs C3 convertase formation in CP and LP. | Undetermined | Undetermined | (23, 24) |
| Trypanosoma cruzi calreticulin (TcCalr) | TcCalr is a 45 kDa protein expressed on the parasite surface and secreted that inhibits the CP and LP in initial step of activation. TcCalr binds to C1, MBL and L-Ficolin. | TcCalr is highly immunogenic in humans and mice and binds C1q, promoting infectivity. Additionally, TcCalr inhibits angiogenesis and tumor growth. Highly immunogenic in humans and mice. | Recombinant TcCalr and DNA-based immunization promote higher parasitemias. Anti - TcCalr F(ab')2 antibody fragments reduce parasitemia and increase survival in mice. | (22, 25–29) |
| Trypomastigote Decay-Accelerating Factor (T-DAF) | T-DAF is an 87-93 kDa glycoprotein expressed on the parasite surface that interferes with assembly of the C3 and C5 convertase of both CP, LP (probably) and AP. | TcCRP is highly immunogenic and induces lytic antibodies in humans and mice. | TcCRP DNA-based immunization protects against T. cruzi infection in mice. | (17–19, 31–34) |
| Trypanosoma cruzi Complement Regulatory Protein (TcCRP) | TcCRP is a glycoprotein, also named gp160, expressed on the parasite surface that binds C3b and C4b, inhibiting the CP and AP C3 convertase. TcCRP inhibits the CP, LP (probably) and AP. | Gp58/68 is a 58-68 kDa protein expressed on the parasite surface that interferes with the C3 convertase formation by binding Factor B, thus specifically inhibiting the AP. | Undetermined | (16, 35) |
| Glycoprotein 58/68 (Gp58/68) | Gp58/68 is a 58-68 kDa protein expressed on the parasite surface that interferes with the C3 convertase formation by binding Factor B, thus specifically inhibiting the AP. | | | |

CP, Classical pathway; LP, Lectin pathway; AP, Alternative pathway; C, Complement system.

TcCalr is shown to bind C1q (58) and possibly recognized by cC1qR (a membrane-bound CARL form) present on the placental syncytiotrophoblast. This interaction is also inhibited by polyclonal F(ab')2 anti-TcCalr antibodies, a fact reflected in lower parasite infectivity in an ex vivo experimental model. An in vivo infectivity inhibitory capacity for anti-TcCalr antibody fragments can be envisaged, considering that, in humans, congenital transmission ranges from 2% to 13.8% in different studies (59).

As mentioned, TcCalr also binds to MBL and L-Ficolin (22, 27). However, the potential role of TcCalr-MBL or TcCalr-Ficolin interactions, in the infectivity process, requires additional research. One study comparing two T. cruzi strains, susceptible and resistant to C, suggested that MBL also participates in the infectivity process while the parasite deactivates the LP (60). Nevertheless, the complete inactivation of the LP does not confer higher susceptibility to the infection since, mice deficient in MASP-2 show similar parasitemia and survival compared to wild-type (61). This fact may indicate that the LP is not essential to control parasitemia and infectivity. However, low levels of L-Ficolin and FCN2 (gene codifying for L-Ficolin) polymorphism are associated with chronic Chagas disease (62).

Based on in silico structural TcCalr models, an interesting peptide (VC-TcCalr), at the TcCalr N-domain, has been delimited and chemically synthesized. VC-TcCalr is a strong dipole, spatially stable (more than its CALR counterpart), that interacts with collagen-like tails and scavenger receptors. This peptide binds to C1q and was anti-angiogenic in a Gallus gallus chorioallantoic membrane assays (63). This crystallographic structural study defines CALR conformational rearrangements that could be informative in future therapeutic investigations of parasite CALR (64), mainly in its anti-complement and anti-neoplastic effects.

**T. CRUZI MOLECULES THAT INHIBIT C3 AND C5 CONVERTASES**

Metacyclic, bloodstream and tissue culture-derived T. cruzi trypomastigotes express an 87-93 kDa glycoprotein (T-DAF), with decay accelerating activity on the CP and AP C3 and C5 convertases (20, 21). This activity was previously found in human decay-accelerating factor (DAF), a 70 kDa glycosphospholipid-anchored membrane protein. DAF is present on erythrocytes, neutrophils, lymphocytes, monocytes, platelets, and endothelial cells (65). T-DAF is functionally, but not structurally analogous to human DAF (21). T-DAF mRNA levels are lower in C-susceptible strains (41). A partial T-DAF cDNA clone and its deduced protein sequence showed 40% homology with a portion of the coding region for DAF (21). T-DAF is immunogenic in experimental animals, inducing antibodies with parasitic lysis capacity (21). Additionally, antibodies against T-DAF were identified in patients chronically infected with T. cruzi (21, 66, 67); thus, T-DAF is highly immunogenic in both humans and mice, suggesting a serodiagnosis value (30).

T. cruzi C regulatory protein (TcCRP), also named gp160, is a 160 kDa GPI-anchored glycoprotein (17) that can be spontaneously released by the trypomastigotes. This protein can inhibit both the CP and AP and stable TcCRP-transfected
epimastigotes were found to be protected from C-mediated lysis (31). There are multiple copies of TcCRPs in the T. cruzi genome, highlighting the importance of this protein for T. cruzi. The encoded proteins are not only structurally and functionally similar to DAF (17, 18, 31), but are also similar to members of the T. cruzi-Trans-Sialidase (TS) superfamily (68). Proteins from this superfamily have enzymatic capacity to transfer monosaccharides from host sialyl-glycoconjugates to terminal β-galactoses of acceptor molecules located on the parasite surface, thus contributing to the parasite survival. However, this superfamily is classified in eight groups, where only group-I has enzymatic activity, and groups II-VIII are considered inactive (68). TcCRP promotes evasion of immune response, in a TS-independent manner (69–71). As expected, positive correlations between the virulence of T. cruzi strains and TcCRP expression levels (72) or mRNA levels (41) have been described. Moreover, TcCRP is immunogenic and induces lytic antibodies in humans and mice (32) and a DNA-based immunization confers protection against T. cruzi infection in mice (33). The levels of lytic antibodies induced by TcCRP in mice infected with different T. cruzi strains suggested that higher levels of parasitemia resulted in an increased exposure of TcCRP and other proteins, which bind to lytic antibodies present in the host’s blood (34). Thus, humoral immune responses, including lytic antibody secretion, could play a role in the later replication cycle, promoting phagocytosis and cellular cytotoxicity to control the infection (34). Additionally, TcCRP is phylogenetically similar to FL-160, a TS-like protein located in the T. cruzi flagellum and flagellar pocket, with still unexplored functions (73). FL-160 derived peptides, presented by the MHC class I pathway (74) (recognized by CD8+ T cells), may have a pathogenic or protective role in chronic Chagas disease (75).

Trypomastigote glycoprotein 58/68 (gp 58/68) (58 or 68 kDa, under non-reducing or reducing conditions, respectively) (35) also inhibits C. In cell-bound and fluid-phase conditions, the protein is shown to have a dose-dependent decay-accelerating activity on the AP C3 convertase formation. However, it does not enhance the decay-dissociation of preformed AP C3 convertases and does not serve as a co-factor for Factor I (FI). Therefore, its inhibitory effect may depend on its interaction with Factor B rather than with C3b (16).

**OTHER MOLECULES AND MECHANISMS RELATED TO T. CRUZI C EVASION**

Factor H (FH), a 155 kDa fluid-phase C negative regulatory protein, composed of 20 short consensus repeats (SCR) (76, 77), can accelerate the decay of the surface-bound AP C3 and C5-convertases (78). In T. cruzi, FH binds with higher affinity to C3b bound to metacyclic trypomastigotes than to epimastigotes (36). FH uses 3 specific sites (79, 80) to interact with unique domains on C3b (79, 81–83), participates as a cofactor for Factor I (FI) and interacts with sialic acid and other related molecules (78, 84, 85). This property is important for T. cruzi, because the parasite has TS to transfer the polyanion α (2, 3)-linked sialic acid from serum glycoconjugates to acceptor sites on the parasite surface (86, 87). These glycoconjugates contribute to regulate C activation on the parasite surface, thus behaving as a virulence factor (88–91). As sialylated molecules downregulate AP activation (92, 93), these polyanions transferred by TS on the trypomastigote surface may also be critical for survival in the circulation (94, 95). This is supported by other studies that highlight the relationship between FH and sialic acid to control C activity in parasites such as Toxoplasma gondii (96), Plasmodium falciparum (97–99) and Echinococcus granulosus cysts (100). Moreover, a positive correlation has been described between FH plasma level and inflammation, cardiac involvement and cardiometabolic parameters in chronic Chagas disease (101).

Extracellular vesicles (EVs) are described in several infectious- and non-infectious diseases and stress (102–107). Bloodstream and endothelial cells release EVs from their cellular membranes (107–110). EVs participate in intercellular communication, transferring glycoproteins, lipids, nucleic acids, and other biomolecular cargos. EVs may play an important role in the parasite-host cell dynamics and in the physiopathology of Chagas disease (111). T. cruzi trypomastigotes are exposed to host cell EVs and also induce EVs release from blood cells in a Ca²⁺-dependent manner. These vesicles bind to C3 convertase, inhibiting the catalytic activity of both the CP and LP (37). On the other hand, EVs with a TGF-β cargo promote host cell invasion via the lysosome-independent route. This phenomenon is dose- and parasite- infective stage dependent and non-specific for parasite strains or host cell types (37). In agreement with this, higher levels of TGF-β are found circulating in chronically infected patients (112). Thus, TGF-β-bearing EVs could activate the TGF-β signaling pathway to promote parasite infectivity (37). Simultaneously, T. cruzi produces exosomes that stimulate different host cells to produce EVs and modulate the immune response (37, 113). EVs contribute to C-resistance and infectivity in trypomastigotes (114), but this response is strain-dependent since EVs derived from a more C-resistant strain can affect infectivity rate of another more susceptible T. cruzi strain (115). On the other hand, infected mice in the presence of T. cruzi-derived EVs present higher parasitemia (37, 116), and mice pre-inoculated with EVs, before infection, register higher mortality or severe pathology (117). The composition of EVs has been evaluated by proteomic and transcriptomic analysis. However, the size, amount and composition may vary according to strain, origin and life cycle stage, among others. Thus, EVs contain proteins related with metabolism, signaling, and virulence, some of them related with C evasion, such as TcCalr (115, 117–119).

**FUTURE THERAPEUTIC PERSPECTIVE**

Efforts to control Chagas disease have been mainly focused on programs aimed at the triatomine vectors. However, there is an urgent need to design new therapeutic and/or preventive tools since current treatments are not completely efficient and are seriously complicated by deleterious side effects (120).
Cytoregulatory proteins released by *T. cruzi* may represent therapeutic or immunogenic/antigenic targets. Given the importance of the C role in innate and adaptive immune response and that *T. cruzi* adopts various strategies to evade C, it is unfortunate that majority of response and that therapeutic or immunogenic/antigenic targets. Given the regulatory proteins released by proteins with enzymatic roles can be ascertained. This inhibition since some of these proteins share mechanisms of they are not completely homologous to their human counterparts. However, since some of these proteins share mechanisms of action, inactivation of one molecule may cause inhibition at different levels or pathways of C activation. Therefore, the site of action of candidate molecules must be carefully experimentally dissected out. Another unexplored possibility is to consider targeting the interaction of C regulatory proteins that is being hijacked by *T. cruzi*. The specific inhibition of catalytic sites of proteins with enzymatic roles can be ascertained. This inhibition could be performed by antibodies, nanobodies, partially or completely humanized monoclonal antibodies or natural or synthetic competitor molecules.

**AUTHORS CONTRIBUTIONS**

GR-T, VF, and AF contributed equally to the generation of this review. GR-T prepared the figure. GR-T, VF, and AF edited the text. LA-G, CV, and SM contributed substantially to the writing, researching previous published works, revision and approved the submitted version. All authors contributed to the article and approved the submitted version.

**FUNDING**

The University of Toledo Biomedical Research Innovation Program (VF), Toledo, Ohio, USA; VID, University of Chile (AF); FONDECYT-Chile 1130099 (AF), CONICYT-REDES 170126 and FIV-FAVET 1210T1701-9102-181 (GR-T).

**REFERENCES**

1. Fernandes HJ, Barbosa LO, Machado TS, Campos JP, Moura AS. Meningoencephalitis Caused by Reactivation of Chagas Disease in Patient Without Known Immunosuppression. *Am J Trop Med Hyg* (2017) 96(2):292–4. doi: 10.4269/ajtmh.16-0225

2. Angheben A, Boix L, Buonfante D, Gobbi F, Bisio Z, Pupella S, et al. Chagas Disease and Transfusion Medicine: A Perspective From Non-Endemic Countries. *Blood Transfus* (2015) 13(4):540–50. doi: 10.2450/2015.0040-15

3. Maguire BJ, Dahal P, Rashan S, Ngu R, Boon A, Forsyth C, et al. The Chagas Disease Study Landscape: A Systematic Review of Clinical and Observational Antiparasitic Treatment Studies to Assess the Potential for Establishing an Individual Participant-Level Data Platform. *PLoS Negl Trop Dis* (2021) 15(8):e0009697. doi: 10.1371/journal.pntd.0009697

4. WHO. Chagas Disease (Also Known as American Trypanosomiasis). (2021). Available at: https://www.who.int/news-room/fact-sheets/detail/chagas-disease--american-trypanosomiasis.

5. Alvedro A, Gaspe MS, Milbourn H, Macchiaverna NP, Laino MA, Enriquez GF, et al. Trypanosoma cruzi Infectious in Triatoma Infestans and High Levels of Human–Vector Contact Across a Rural-to-Urban Gradient in the Argentine Chaco. *Parasit Vectors* (2021) 14(1):35. doi: 10.1186/s13071-020-04534-z

6. Fabrizio MC, Schweigmann NJ, Bartoloni NJ. Modelling Inter–Human Transmission Dynamics of Chagas Disease: Analysis and Application. *Parasitology* (2014) 141(6):837–48. doi: 10.1017/S003118201302199

7. Ingber A, Garcia MN, Leon J, Murray KO. Chagas Disease Knowledge and Risk Behaviors of the Homeless Population in Houston, TX. *J Racial Ethn Health Dispar* (2018) 5(2):229–34. doi: 10.1007/s40615-017-0362-0

8. Perez CJ, Lymberry AJ, Thompson RCA. Reactivation of Chagas Disease: Implications for Global Health. *Trends Parasitol* (2015) 31(11):595–603. doi: 10.1016/j.pt.2015.06.006

9. Cetron MS, Basilio FP, Moraes AP, Sousa AQ, Paes JN, Kahn SJ, et al. Humoral and Cellular Immune Response of Adults From Northeastern Brazil With Chronic Trypanosoma cruzi Infection: Depressed Cellular Immune Response to *T. cruzi* Antigen Among Chagas’ Disease Patients With Symptomatic Versus Indeterminate Infection. *Am J Trop Med Hyg* (1993) 49(3):370–82. doi: 10.4269/ajtmh.1993.49.370

10. Hayes MM, Kierszenbaum F. Experimental Chagas’ Disease: Kinetics of Lymphocyte Responses and Immunological Control of the Transition From Acute to Chronic Trypanosoma cruzi Infection. *Infect Immun* (1981) 31(3):1117–24. doi: 10.1128/iai.31.3.1117-1124.1981

11. Zufiuga E, Mo trout C, Montes CL, Diaz FL, Bocco JL, Gruppi A. Trypanosoma cruzi-Induced Immunosuppression: B Cells Undergo Spontaneous Apoptosis and Lipopolysaccharide (LPS) Arrest Their Proliferation During Acute Infection. *Clin Exp Immunol* (2000) 119(3):507–15. doi: 10.1046/j.1365-2249.2000.01150.x

12. Ortega Zamora Y, Escamilla Rojas LJ, Villa Sandoval EM, Vela Porrás JS, Cossio Contraera EY, Cubides Romero SS, et al. Chagas Disease Immunogenetics: Elusive Markers of Disease Progression. *Expert Rev Cardiovasc Ther* (2017) 15(5):367–76. doi: 10.1080/14799507.2017.1317591

13. Muniz J, Borriello A. Study on the Liturgical Action of Different Places on the Culture and Blood Forms of Schizotrypanum cruzi. *Rev Bras Biol* (1945) 5:563–76.

14. Rubio M. Lytic Effect of Normal Sera on Cultured and Sanguineous Forms of Trypanosoma cruzi. *Bol Chil Parasitol* (1956) 11(4):62–9.

15. Cestari I, Ramirez MI. Inefficient Complement System Clearance of Trypanosoma cruzi Metacyclic Trypomastigotes Enables Resistant Strains to Invade Eukaryotic Cells. *PLoS One* (2010) 5(3):e9721. doi: 10.1371/journal.pone.0009721

16. Fischer E, Ouaisi MA, Velge P, Cornette J, Kazatchkine MD. Gp 58/68, a Parasite Component That Contributes to the Escape of the Trypomastigote Form of *T. cruzi* From Damage by the Human Alternative Complement Pathway. *Immunology* (1998) 65(2):299–303.

17. Norris KA, Bradt B, Cooper NR, So M. Characterization of a Trypanosoma cruzi C3 Binding Protein With Functional and Genetic Similarities to the Human Complement Regulatory Protein, Decay-Accelerating Factor. *J Immunol* (Baltimore Md 1950) (1991) 147(7):2240–7.

18. Norris KA, Schrimpf JE. Biochemical Analysis of the Membrane and Soluble Forms of the Complement Regulatory Protein of Trypanosoma cruzi. *Infect Immun* (1994) 62(1):236–43. doi: 10.1128/iai.62.1.236-243.1994

19. Beucher M, Meira WS, Zegarra V, Galvao LM, Chiari E, Norris KA. Expression and Purification of Functional, Recombinant Trypanosoma cruzi Complement Regulatory Protein. *Protein Expr Purif* (2003) 27(1):19–26. doi: 10.1016/s1046-5928(02)00562-4

20. Kipnis TL, Joiner KA, da Silva WD, Rimoldi MT, Hammer CH, Sher A. Identification of Membrane Components of Trypanosoma cruzi Modulators of Complement System. *Memorias do Inst Oswaldo Cruz* (1988) 83(Suppl 1):571–5. doi: 10.1590/S0074-02671988000500069
21. Tambourgi DV, Kipnis TL, da Silva WD, Joiner KA, Sher A, Heath S, et al. A Partial cDNA Clone of Trypomastigote Decay-Accelerating Factor (T-DAF), a Developmentally Regulated Complement Inhibitor of Trypanosoma cruzi, has Genetic and Functional Similarities to the Human Complement Inhibitor DAF. *Infect Immun* (1993) 61(9):3656–63. doi: 10.1128/iai.61.9.3656-3663.1993

22. Ferreira V, Valck C, Sanchez G, Gingras A, Tzima S, Molina MC, et al. The Classical Activation Pathway of the Human Complement System Is Specifically Inhibited by Calreticulin From Trypanosoma cruzi. *J Immunol* (Baltimore Md 1950) (2004) 172(5):3042–50. doi: 10.4049/jimmunol.172.5.3042

23. Cestari Idos S, Evans-Osses I, Freitas JC, Inal JM, Ramirez MI. Role of Early Lectin Activation by Direct Interaction With L-Ficolin. *BMC Cancer* (2010) 4(7):e730. doi: 10.1186/1471-2407-10-730

24. Cestari Idos S, Krarup A, Sim RB, Inal JM, Ramirez MI. Complement Pathway Activation in the Complement-Mediated Killing of Trypanosoma cruzi. *PLoS Negl Trop Dis* (2014) 8(2):e2696. doi: 10.1371/journal.pntd.0002696

25. Lopez NC, Valck C, Ramirez G, Rodriguez M, Ribeiro C, Orellana J, et al. Anticancer Properties of Flagellate Protozoan Trypanosoma cruzi Calreticulin. *Am J Trop Med Hyg* (1995) 52(6):516. doi: 10.4269/ajtmh.1995.52.516

26. Sanchez-Valdez FJ, Perez Brandon C, Ramirez G, Uncos AD, Zago MP, Cimino RC, et al. Monoallelic Deletion of the TcCRT Gene Increases the Attenuation of a Cultured Trypanosoma cruzi Strain, Protecting Against an *In Vivo* Virulent Challenge. *PLoS Negl Trop Dis* (2014) 8(2):e2696. doi: 10.1371/journal.pntd.0002696

27. Valck C, Ramirez G, Lopez N, Ribeiro CH, Maldonado I, Sanchez G, et al. Molecular Mechanisms Involved in the Inactivation of the First Component of Human Complement by Trypanosoma cruzi Calreticulin. *Mol Immunol* (2010) 47(7-8):1516–21. doi: 10.1016/j.molimm.2010.01.019

28. Sosoniuk E, Vallejos G, Kenawy H, Gaboriaud C, Thielen N, Fujita T, et al. Trypanosoma cruzi Calreticulin Inhibits the Complement Lectin Pathway Activation by Direct Interaction With L-Ficolin. *Mol Immunol* (2014) 60 (1):80–5. doi: 10.1016/j.molimm.2013.04.014

29. Ramírez G, Valck C, Molina MC, Ribeiro CH, Lopez N, Sanchez G, et al. Trypanosoma cruzi Calreticulin: A Novel Virulence Factor That Binds Complement C1 on the Parasite Surface and Promotes Infectivity. *Immunobiology* (2011) 216(1-2):265–73. doi: 10.1016/j.immuni.2010.04.001

30. Tambourgi DV, Cavinato RA, De Abreu CM, Peres BA, Kipnis TL, Detection of Trypanosoma-decay Accelerating Factor Antibodies in Mice and Humans Infected With Trypanosoma cruzi. *Am J Trop Med Hyg* (1995) 52(5):516–20. doi: 10.4269/ajtmh.1995.52.516

31. Norris KA. Stable Transformation of Trypanosoma cruzi Epimastigotes With the Trypomastigote-Specific Complement Regulatory Protein cDNA Confers Complement Resistance. *Infect Immun* (1998) 66(6):2460–5. doi: 10.1128/IAI.66.6.2460-2465.1998

32. Martins MS, Hudson L, Kretti AU, Cançado JR, Brener Z. Human and Mouse Sera Recognize the Same Polypeptide Associated With Immunological Resistance to Trypanosoma cruzi Infection. *Clin Exp Immunol* (1985) 61(2):343–50.

33. Sepulveda P, Hontebeyrie M, Liegard P, Mascilli A, Norris KA. DNA-Based Immunization With Trypanosoma cruzi Complement Regulatory Protein Elicits Complement Lytic Antibodies and Confers Protection Against *Trypanosoma cruzi* Infection. *Infect Immun* (2000) 68(9):4986–91. doi: 10.1128/iai.68.9.4986-4991.2000

34. Marques T, Silva GC, Henrique Paiva PM, Nascentes GAN, Ramirez LE, Norris K, et al. Use of Tc-1 C1R as a Target for Lytic Antibody Titration After Experimental Trypanosoma cruzi Infection. *Exp Parasitol* (2018) 184:103–8. doi: 10.1016/j.exppara.2017.12.003

35. Valck C, Ramirez G, Valck C, Molina MC, Rosas C, Pena J, et al. F(ab')2 Antibody Fragments Against Trypanosoma cruzi Calreticulin Inhibit Its Interaction With the First Component of Human Complement. *Biochem Biophys Res Commun* (2005) 328(2-3):187–95. doi: 10.1016/j.bbrc.2005.02.0008

36. Sosoniuk-Roche E, Vallejos G, Aguilar-Guzman L, Pizarro-Bauerle J, Weinberger K, Rosas C, et al. Exogenous Calreticulin, Incorporated Onto Non-Infective Trypanosoma cruzi Epimastigotes, Promotes Their Internalization Into Mammal Host Cells. *Immunobiology* (2017) 222 (3):529–35. doi: 10.1016/j.imjbio.2016.10.020
55. Crawford K, Kalionis B, Stevenson J, Brennecke S, Gude N. Calreticulin has 
Opposing Effects on the Migration of Human Trophoblast and Myometrial 
Endothelial Cells. *Placenta* (2012) 33(5):416–23. doi: 10.1016/ 
pla.2012.02.003
56. Gu V, Wong M, Stevenson J, Crawford K, Brennecke S, Gude N. Calreticulin in 
Human Pregnancy and Pre-Eclampsia. *Mol Hum Reprod* (2008) 14 
(5):309–15. doi: 10.1093/molehr/gan017
57. Houen G, Koch C. Human Placental Calreticulin: Purification, 
Characterization and Association With Other Proteins. *Acta Chim 
Scand* (1994) 48(11):905–11. doi: 10.3891/acta.chim.scand.48-0905
58. Castillo C, Ramirez G, Valck C, Aguilar L, Maldonado I, Rosas C, et al. 
The Interaction of Classical Complex Component C1 With Parasite and 
Host Calreticulin Mediates Trypanosoma cruzi Infection of Human Placenta. *PLoS 
Negl Trop Dis* (2013) 7(8):e2376. doi: 10.1371/journal.pntd.0002376
59. Llanes-Garcia J, Wikman-Jorgensen P, Gil-Anguita C, Ramos-Sesma V, 
Torrué-Tendero D, Martinez-Goñi R, et al. Chagas Disease Screening in 
Pregnant Latin American Women: Adherence to a Systematic Screening 
Protocol in a Non-Endemic Country. *PLoS Negl Trop Dis* (2021) 15(3): 
e0099281. doi: 10.1371/journal.pntd.0009928
60. Evans-Osses I, Mojoli A, Beltrame MH, da Costa DE, DaRoacha WD, 
Velan TP, et al. Differential Ability to Resist to Complement Lysis and 
Invade Host Cells Mediated by MLB in R4 and 860 Strains of Trypanosoma 
 cruzi. *FEBS Lett* (2014) 588(6):956–61. doi: 10.1016/j.febslet.2014.01.054
61. Baeza-Huertas CH, Lynch NF, Stover CM, Ah YM, Valck C, Noya-Leal F, et al. 
Deficiency in Mannose-Binding Lectin-Associated Serine Protease-2 Does 
Not Increase Susceptibility to Trypanosoma cruzi Infection. *Am J Trop 
Med Hyg* (2015) 92(2):320–4. doi: 10.4269/ajtmh.14-0236
62. Luz PR, Boldt ABW, Grishbach C, Kun JF, Velan TP, Messias-Reason JI. 
Association of L-Ficolin Levels and FCN2 Genotypes With Chronic Chagas Disease. 
*PLoS One* (2013) 8(4):e60237. doi: 10.1371/journal.pone.0060237
63. Peña A, Henrique PM, Marques T, da Silva MV, Nascentes GA, de Oliveira CF, 
Mathieu-Daudé F, Lafay B, Touzet O, Lelièvre J, Parrado F, Bosseno MF, 
and the Exploring the FL-160-CRP Gene Family Through Sequence Variability of 
the Complement Regulatory Protein (CRP) Expressed by the 
Trypanostatic Stage of Trypanosoma cruzi. *Infect Genet Evol* (2008) 8 
(3):258–66. doi: 10.1016/j.mge.2007.12.010
64. Garg N, Nunes MP, Tarleton RL. Delivery by Trypanosoma cruzi of Proteins 
Into the MHC Class I Antigen Processing and Presentation Pathway. 
*J Immunol (Baltimore Md 1950)* (1997) 158(7):3293–302.
65. Fonseca SG, Moinis-Teisserenc H, Clave E, Ianni B, Nunes VL, Mady C, et al. 
Identification of Multiple HLA-A*0201-Restricted czipain and FL-160 
CD4+ Epitopes Recognized by T Cells From Chronically Trypanosoma 
 cruzi-Infected Patients. *Microbes Infect* (2005) 7(4):688–97. doi: 10.1016/ 
j.micinf.2005.01.001
66. Christensen T, Tack BF. Murine Protein H Is Comprised of 20 Repeating 
Units, 61 Amino Acids in Length. *Proc Natl Acad Sci USA* (1986) 83 
(11):3963–7. doi: 10.1073/pnas.83.11.3963
67. Ripoche J, Day AJ, Harris TJ, Sim RB. The Complete Amino Acid Sequence 
of Human Complement Factor H. *Biochem J* (1988) 249(2):593–602. 
doi: 10.1042/bj02490593
68. Pangburn MK. Host Recognition and Target Differentiation by Factor H, a 
Regulator of the Alternative Pathway of Complement. *Immunopharmacology* 
(2000) 49(1-2):149–57. doi: 10.1016/s0162-3109(00)03030-8
69. Sharma AK, Pangburn MK. Identification of Three Physically and 
Functionally Distinct Binding Sites for C3b in Human Complement Factor 
H by Deletion Mutagenesis. *Proc Natl Acad Sci USA* (1996) 93 
(20):10996–1001. doi: 10.1073/pnas.93.20.10996
70. Haque A, Cortes C, Alam MN, Sreedhar M, Ferreira VP, Pangburn MK. 
Characterization of Binding Properties of Individual Functional Sites of 
Human Complement Factor H. *Front Immunol* (2020) 11:1728. 
doi: 10.3389/fimmu.2020.01728
71. Alsenz J, Schulz TF, Lambris JD, Sim RB, Dierich MP. Structural 
and Functional Analysis of the Complement Component Factor H With the 
Use of Different Enzymes and Monoclonal Antibodies to Factor H. *Biochem 
J* (1985) 232(3):841–50. doi: 10.1042/bj02320841
72. Jokiranta TS, Hellwing J, Koistinen V, Zipfel PF, Meri S. Each of the Three 
Binding Sites on Complement Factor H Interacts With A Distinct Site on 
C3b, *J Biol Chem* (2000) 275(36):27657–62. doi: 10.1074/jbc.M002930200
73. Lambris JD, Avila D, Becherer JD, Muller-Eberhard HJ. A Discontinuous 
Factor H Binding Site in the Third Component of Complement as 
Delineated by Synthetic Peptides. *J Biol Chem* (1988) 263(24):12147–50. 
doi: 10.1016/s0021-9975(17)28390-5
74. Alsenz J, Lambris JD, Schulz TF, Dierich MP. Localization of the 
Complement-Component-C3b-Binding Site and the Cofactor Activity for Factor I in 
the 38kd Tryptic Fragment of Factor H. *Biochem J* (1984) 224 
(2):389–98. doi: 10.1042/bj2240389
75. Kuhn S, Skerka C, Zipfel PF. Mapping of the Complement Regulatory 
Domains in the Human Factor H-Like Protein 1 and in Factor H1. 
*J Immunol (Baltimore Md 1950)* (1995) 155(12):5663–70.
76. Schenkenk S, Jiang MS, Hart GW, Nussenzwang V. A Novel Cell Surface 
Trans-Sialidase of Trypanosoma cruzi Generates a Stage-Specific Epitope 
Required for Invasion of Mammalian Cells. *Cell* (1991) 65(7):1117–25. 
doi: 10.1016/0092-8674(91)90008-r
77. Tomlinson S, Pontes de Carvalho LC, Vanderkerkhove F, Nussenzwang V. 
Role of Sialic Acid in the Resistance of Trypanosoma cruzi Trypanostigotes to 
Complement. *J Immunol (Baltimore Md 1950)* (1994) 153(7):3141–7.
78. Edwards MS, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 
Deposition by Capsular Polysaccharide Is a Virulence Mechanism of Type 
Complement Regulatory Protein Expression Levels, and the Ability to Elicit 
Lytic Antibody Production. *Exp Parasitol* (2016) 170:66–72. doi: 10.1016/ 
exparas.2016.09.001
79. Mathieu-Daudé F, Lafay B, Touzet O, Lelièvre J, Parrado F, Bosseno MF, 
et al. Neutrophil Complement Receptor Interactions With Type III Group B 
Streptococci. *Infect Immun* (1993) 61(7):2866–71. doi: 10.1128/aii.61.7.2866- 
2871.1993
80. Marques MB, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 
Deposition by Capsular Polysaccharide Is a Virulence Mechanism of Type 
Complement Regulatory Protein Expression Levels, and the Ability to Elicit 
Lytic Antibody Production. *Exp Parasitol* (2016) 170:66–72. doi: 10.1016/ 
exparas.2016.09.001
81. Mathieu-Daudé F, Lafay B, Touzet O, Lelièvre J, Parrado F, Bosseno MF, 
et al. Neutrophil Complement Receptor Interactions With Type III Group B 
Streptococci. *Infect Immun* (1993) 61(7):2866–71. doi: 10.1128/aii.61.7.2866- 
2871.1993
82. Marques MB, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 
Deposition by Capsular Polysaccharide Is a Virulence Mechanism of Type
